JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
JB Pharma submitted its FY2025-26 Integrated Annual Report. The company delivered consolidated revenue of ₹4,148 crores (up 6%) with EBITDA of ₹1,178 crores (up 8%) and PAT of ₹709 crores (up 8%). EBITDA margin improved from 27.7% to 28.4%. Domestic formulations grew 11% with the company retaining its #22 ranking in IPM, with 6 brands in the Top 300. A significant management change occurred during the year—Torrent Pharmaceuticals acquired a controlling stake, with a new board including MD Aman Mehta appointed effective January 21, 2026. During Q4, the company undertook restructuring of loss-making segments and domestic distribution, with normalizing of channel inventory internationally, causing temporary one-time impacts. The company operates across 40+ countries, has 8 globally accredited manufacturing facilities, and is among the top 5 global manufacturers of medicated lozenges.
The Torrent acquisition marks a new chapter for JB Pharma, with expected synergies in scale, operations, and market access. Q4 restructuring initiatives should drive long-term cost efficiencies, though near-term volatility in quarterly results may continue as integration progresses.